Facing the hard choice
From the 1978 Mardi Gras to today: the risks of activism as a pharmacist. By Deni Salmon, founder of the Queer Pharmacists of Australia group At around 10 p.m. on …
Franchising: The legal view
Pharmacy owners should take their time before committing to a franchise or banner group deal, says Sarah Stoddart, director of Vitality Law Australia. Stoddart told the AJP that pharmacists looking …
NSW Health vaccine storage and cold chain audits
Pharmacies participating in the NIPVIP program are being reminded of their obligations relating to vaccine storage On behalf of NSW Health, local Public Health Units (PHUs) may carry out random …
Consumer focus boosts Wesfarmers
Priceline shines for Wesfarmers while wholesaler deal could give gloss to sluggish API, reports Mike Taylor While most of the attention since the beginning of 2025 has been on the …
Capital Gains Tax – what it means for you
Capital Gains Tax is one of those concepts business owners and investors know about but don’t always fully understand, writes Priya Narsing, a director at Peak Strategies. It can have …
‘Canberra policy bubble no fix for cost of living’
Interest rate relief is great, but it doesn’t touch the sides of the cost-of-living crisis… and if you’re renting, it’s unlikely to make much difference at all, writes Guild national …
Medicinal cannabis risk mitigation
Medicinal cannabis is still an emerging part of pharmacy practice… PDL has some tips and advice based on recent incident reports and professional practice enquiries There has been an increase …
Extended scope of practice reminder
PDL has a reminder to NSW pharmacists and pharmacy owners about extended scope of practice With many pharmacies now offering extended scope of practice services across NSW, it is important …
Strategies to drive your pharmacy in the new year
There are at least six key areas to focus on to help make a fresh, optimistic start to the new year for your pharmacy, says Rebecca Goodsell of Peak Strategies …
February MIMS update
Some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products RelabotulinumtoxinA (Relfydess) is a Clostridium botulinum type A neurotoxin product that blocks the …
January MIMS Update
Some of the recent changes to the medicines landscape, with new products, indications and safety-related changes New Products Amivantamab (Rybrevant) is a low-fucose, fully-human IgG1-based bispecific antibody that binds to …
